Elicio Therapeutics (ELTX) EBITDA (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of EBITDA data on file, last reported at -$11.8 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 5.73% year-over-year to -$11.8 million; the trailing twelve-month figure through Mar 2026 stood at -$40.2 million (up 21.49% YoY), and the FY2025 full-year result was -$39.5 million, up 23.81% from the prior year.
• EBITDA for Q1 2026 stood at -$11.8 million, down from -$7.8 million in the prior quarter.
• Across five years, EBITDA topped out at -$6.7 million in Q4 2022 and bottomed at -$18.8 million in Q3 2024.
• The 5-year median for EBITDA is -$10.0 million (2025), against an average of -$10.2 million.
• Peak annual rise in EBITDA reached 60.87% in 2022, while the deepest fall reached 144.76% in 2022.
• A 5-year view of EBITDA shows it stood at -$6.7 million in 2022, then tumbled by 37.14% to -$9.1 million in 2023, then plunged by 53.24% to -$14.0 million in 2024, then soared by 44.09% to -$7.8 million in 2025, then slumped by 51.24% to -$11.8 million in 2026.
• The last three EBITDA figures came in at -$11.8 million (Q1 2026), -$7.8 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.

Peer Comparison